Work

Belzutifan in docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Phase 1b/2 KEYNOTE-365 cohort J.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5058

Authors: Jose Angel Arranz Arija, Gedske Daugaard, Niven Mehra, Tilman Todenhoefer, Howard Gurney, Margitta Retz, Josep M. Piulats, Julie N. Graff, Alessandra Mosca, Daniel Vaena, Christopher Eing Wee, Capucine Baldini, Ahmed H. Zedan, Lockman Bousserouel, Charles Schloss, Kentaro Imai, Evan Y. Yu

Institutions: Hospital General Universitario Gregorio Marañón, Copenhagen University Hospital, Rigshospitalet, Radboud University Medical Center, Praxis für Humangenetik Tübingen, Macquarie University, TUM Klinikum, Technical University of Munich, Institut Català d'Oncologia, Portland VA Medical Center, Candiolo Cancer Institute, West Cancer Center, Cleveland Clinic, Institut Gustave Roussy, Fondation Gustave Roussy, Vejle Sygehus, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162500585

Cites:

Cited by:

Related to: